Clinical Trial: High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07177079) titled 'High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)' on Sept. 09.

Brief Summary: This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in newly diagnosed AML.

Study Start Date: Dec. 31, 2025

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia

Intervention: DRUG: Azacitidine

A chemotherapy drug known as a hypomethylating agent

DRUG: Venetoclax

Targeted cancer therapy used to treat certain blood cancers. It sp...